Bacterial characteristics of carbapenem-resistant Enterobacteriaceae (CRE) colonized strains and their correlation with subsequent infection
Authors:
Open Access
- 2 July 2021
- journal article
- research article
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 21 (1) , 1-12
Abstract
Background: Searching the risk factors for carbapenem-resistant Enterobacteriaceae (CRE) infection is important in clinical practice. In the present study, we aim to investigate bacterial characteristics of colonizing strains and their correlation with subsequent CRE infection. Methods: Between May 2018 and January 2019, patients hospitalized in the department of haematology and intensive care unit (ICU) were screened for CRE by rectal swabs and monitored for the outcome of infection. We identified the species and carbapenemase-encoding genes of colonizing strains and performed antimicrobial susceptibility tests and multilocus sequence typing (MLST). Risk factors for subsequent CRE infections were ascertained by univariate and multivariable analysis. Results: We collected a total of 219 colonizing strains from 153 patients. Klebsiella pneumoniae was the most abundant species, and MLST analysis showed rich diversity. K. pneumoniae carbapenemase (KPC) was predominant in the infection group (72.4%). In the non-infection group, 35.4% of strains were non-carbapenemase-producing CRE (NCP-CRE), and New Delhi metallo-β-lactamase (NDM) was predominant (42.2%). The rate of high-level carbapenem resistance (minimum inhibitory concentration [MIC] ≥ 64 mg/L for meropenem and ertapenem, ≥ 32 mg/L for imipenem) was remarkably higher in the infection group than in the non-infection group (P < 0.001). Univariate analysis showed that K. pneumoniae, high-level carbapenem resistance, CP-CRE and KPC-CRE were infection risk factors after CRE colonization. On multivariable analysis with different carbapenemase dichotomizations, KPC-CRE (adjusted odds ratio [aOR], 4.507; 95% confidence interval [CI], 1.339–15.171; P = 0.015) or imipenem MIC ≥ 32 mg/L (aOR, 9.515; 95% CI, 1.617–55.977; P = 0.013) were respectively identified as independent risk factors for subsequent infection. Conclusions: Patients colonized with KPC-CRE or strains with an imipenem MIC ≥ 32 mg/L were at particularly high risk of subsequent CRE infections during their hospital stay.Keywords
Funding Information
- National Mega Project on Major Infectious Disease Prevention (2017ZX10103005-007)
- Natural Science Foundation of Hubei (2019CFB666)
This publication has 38 references indexed in Scilit:
- Treating infections caused by carbapenemase-producing EnterobacteriaceaeClinical Microbiology and Infection, 2014
- Oral Gentamicin Gut Decontamination for Prevention of KPC-Producing Klebsiella pneumoniae Infections: Relevance of Concomitant Systemic Antibiotic TherapyAntimicrobial Agents and Chemotherapy, 2014
- Rapid emergence of secondary resistance to gentamicin and colistin following selective digestive decontamination in patients with KPC-2-producing Klebsiella pneumoniae: a single-centre experienceInternational Journal of Antimicrobial Agents, 2013
- Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemasesThe Lancet Infectious Diseases, 2013
- Prevalence and Risk Factors for Acquisition of Carbapenem-Resistant Enterobacteriaceae in the Setting of EndemicityInfection Control & Hospital Epidemiology, 2013
- Risk factors for bloodstream infection with Klebsiella pneumoniae producing VIM-1 metallo- -lactamaseJournal of Antimicrobial Chemotherapy, 2010
- Development of a set of multiplex PCR assays for the detection of genes encoding important β-lactamases in EnterobacteriaceaeJournal of Antimicrobial Chemotherapy, 2010
- Carbapenemase-producing Enterobacteriaceae , U.S. RiversEmerging Infectious Diseases, 2005
- First Class A Carbapenemase Isolated from Enterobacteriaceae in ArgentinaAntimicrobial Agents and Chemotherapy, 2004
- SME-Type Carbapenem-Hydrolyzing Class A β-Lactamases from Geographically Diverse Serratia marcescens StrainsAntimicrobial Agents and Chemotherapy, 2000